Alloga UK Ltd Pharmaceutical Import Profile — United Kingdom (DGFT 2022–2026)

Name: Alloga UK Ltd Pharmaceutical Import Records from India — 6 Products, $11.1M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Alloga UK Ltd — Pharmaceutical Importer Profile (2026) | 6 Products, $11.1M Trade | TransData Nexus

Alloga UK Ltd

Pharmaceutical Importer · United Kingdom · Antihistamines & Allergy Focus · $11.1M Total Trade · DGFT Verified

Alloga UK Ltd is a pharmaceutical importer based in United Kingdom with a total trade value of $11.1M across 6 products in 4 therapeutic categories. Based on 563 verified import shipments from Indian Customs (DGFT) records, Alloga UK Ltd is the #1 buyer in 1 product including Methotrexate. Alloga UK Ltd sources from 11 verified Indian suppliers, with Cipla Limited accounting for 84.1% of imports.

Alloga UK Ltd — Import Portfolio & Supplier Network

Alloga UK Ltd import network — 6 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Alloga UK Ltd?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Cipla Limited	$16.0M	2,959	84.1%
Hetero Labs Limited	$958.2K	30	5.0%
Maiva Pharma Private Limited	$548.9K

What Formulations Does Alloga UK Ltd Import?

Formulation	Value	Ships
Sereflo 25 microgram/125 microgramper actuation pressurised inhalation, suspension (inhaler)	$473.9K	20
Soltel cfc-free inhaler 25 micrograms	$462.5K	21
Bibecfo 100/6 micrograms per actuation, pressurised inhalation solution (120 md) (inhaler) (beclomethasone	$357.9K	18
Kelhale 100 (beclometasone dipropionate 100 MCG)	$318.1K	14
Co-codamol 30/500 MG effervescent tabs	$297.0K	89
Treathay 120 MG Film-Coated tablets (fexofenadine 120MG) Pack size 3 x	$263.6K	15
Sereflo 25 microgram/250 microgramper actuation pressurised inhalation, suspension (inhaler)	$253.1K	13
Mometasone furoate 50 micrograms actuation nasal spray suspension mometasone furoate monohydrate nasal suspension	$252.4K	15
Cetirizine hydrochloride 5MG/5ML oral	$244.4K	44
Mometasone furoate 50 micrograms /actuation nasal spray,suspension (mometasone furoate monohydrate nasal suspension	$244.2K	15
Tenofovir dis+emtricitab	$240.7K	6
Kelhale 50 (beclometasone dipropionate 50 MCG).	$228.1K	14
Cetirizine hydrochloride 5MG 5ML oral solution 1 x 200 ML	$204.3K	15
Mometasone furoate 50 micrograms/actuation nasal spray,SUSP.mometasone furoatemonohydrate nasal	$202.1K	12
Mometasone furoate 50	$202.0K	12

Alloga UK Ltd imports 1,159 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 6 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Fexofenadine	Antihistamines & Allergy	$4.3M	227	3.9%	6
2	Methotrexate	Immunosuppressants	$2.8M	56	8.0%	1
3	Salbutamol	Respiratory	$2.5M	88	1.7%	7
4	Codeine	Analgesics & Antipyretics	$1.2M	186	1.1%	6
5	Fluticasone	Respiratory	$150.0K	3	0.1%	12
6	Salmeterol	Respiratory	$150.0K	3	0.2%	3

Alloga UK Ltd imports 6 pharmaceutical products across 4 categories into United Kingdom totaling $11.1M. The company is the #1 buyer for 1 product: Methotrexate.

Alloga UK Ltd — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Alloga UK Ltd, established on 7 March 1996, is a private limited company specializing in the wholesale distribution of pharmaceutical goods. Headquartered in Alfreton, Derbyshire, England, the company operates as a third-party logistics provider dedicated to the pharmaceutical and healthcare sectors. Alloga UK Ltd is part of the Alloga Group, which has over 60 years of experience in healthcare logistics and is a key player in the Swiss healthcare market. The company plays a significant role in the United Kingdom's pharmaceutical distribution network, offering comprehensive logistics and warehousing solutions to pharmaceutical manufacturers, biopharma companies, healthcare providers, and pharmacies.

2Distribution Network

Alloga UK Ltd's distribution network is strategically located to serve the United Kingdom effectively. The company's registered office is situated at Amber Park, Berristow Lane South Normanton, Alfreton, Derbyshire, DE55 2FH. While specific details about additional warehouse locations and logistics capabilities are not publicly disclosed, Alloga UK Ltd's affiliation with the Alloga Group suggests access to a pan-European logistics network spanning 12 countries. This extensive network enables the company to provide timely and temperature-controlled supply services for medicines, ensuring efficient distribution across the United Kingdom and potentially beyond.

3Industry Role

Alloga UK Ltd operates as a third-party logistics provider within the United Kingdom's pharmaceutical supply chain. The company specializes in logistics and warehousing services, facilitating the distribution of pharmaceutical products from manufacturers to end-users. By offering both 'logistics only' and 'full service' models, Alloga UK Ltd enables pharmaceutical partners to outsource storage, order processing, distribution, invoicing, and cash collection, thereby streamlining operations and enhancing service delivery.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Alloga UK Ltd

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Alloga UK Ltd's sourcing strategy exhibits a high degree of concentration, with a significant portion of its pharmaceutical imports originating from India. Between 2022 and 2026, the company imported finished pharmaceutical formulations valued at $11.1 million USD from India, encompassing 563 shipments across 6 products in 4 therapeutic categories. The top five products imported include Methotrexate ($2.8 million, 8.0% share), Fexofenadine ($4.3 million, 3.9% share), Salbutamol ($2.5 million, 1.7% share), Codeine ($1.2 million, 1.1% share), and Fluticasone ($150,000, 0.1% share). Notably, Alloga UK Ltd is the leading buyer of Methotrexate from India. This sourcing pattern indicates a strategic focus on specific therapeutic areas, potentially leveraging favorable pricing, quality, and supply chain efficiencies associated with Indian manufacturers.

2Supply Chain Resilience

Alloga UK Ltd's supply chain resilience is influenced by its concentrated sourcing from Indian suppliers. The company has engaged with 11 unique Indian suppliers, with CIPLA LIMITED accounting for 84.1% of the total import value. This heavy reliance on a single supplier introduces potential risks related to supply disruptions, regulatory changes, or geopolitical factors affecting India. The limited number of suppliers and formulations imported may also impact the company's ability to diversify its product offerings. To enhance supply chain resilience, Alloga UK Ltd could consider expanding its supplier base and diversifying the range of formulations sourced from India.

Importing Pharmaceuticals into United Kingdom — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United Kingdom

1Regulatory Authority & Framework

The Medicines and Healthcare products Regulatory Agency (MHRA) is the primary regulatory authority overseeing pharmaceutical imports into the United Kingdom. Key legislation governing pharmaceutical imports includes the Human Medicines Regulations 2012, which implement European Union directives and set out requirements for the importation, distribution, and sale of human medicines. The MHRA provides guidance on sourcing medicines for the UK market, including the importation of licensed and unlicensed medicines, and the requirements for wholesale distribution licenses and marketing authorizations. (gov.uk)

2Import Licensing & GMP

To import human medicines into the UK, companies must obtain a Wholesale Distribution Authorisation (WDA(H)) from the MHRA. This license permits the wholesale distribution of human medicines and ensures compliance with Good Distribution Practice (GDP) standards. Additionally, a Marketing Authorisation (MA) is required for each medicinal product, confirming that the product has been evaluated and approved for sale in the UK. The MHRA also recognizes Good Manufacturing Practice (GMP) certificates from countries with which it has agreements, facilitating the importation of medicines manufactured in those countries. (gov.uk)

Quality & Labeling

Alloga UK Ltd — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Alloga UK Ltd's product strategy focuses on specific therapeutic areas, including Antihistamines & Allergy, Immunosuppressants, and Respiratory treatments. The company's imports from India are heavily concentrated in these categories, with Methotrexate, Fexofenadine, and Salbutamol being the top three products. This focus aligns with market demand for these treatments in the UK, indicating that Alloga UK Ltd is strategically positioning itself to meet the needs of healthcare providers and patients in these therapeutic areas.

2Sourcing Profile

Alloga UK Ltd's sourcing strategy emphasizes generic drug formulations, particularly in the therapeutic areas of Antihistamines & Allergy, Immunosuppressants, and Respiratory treatments. The company's imports from India are predominantly in these categories, reflecting a preference for cost-effective generic options. India's established pharmaceutical manufacturing capabilities and competitive pricing make it a key supplier for Alloga UK Ltd's procurement needs.

3Market Positioning

Based on its product mix, Alloga UK Ltd serves a diverse segment of the United Kingdom market, including retail pharmacies, hospitals, and wholesale distribution channels. The company's focus on essential therapeutic areas positions it to meet the needs of various healthcare providers and patients, ensuring a broad market presence.

Seller's Guide — How to Become a Supplier to Alloga UK Ltd

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Alloga UK Ltd, particularly by offering a broader range of formulations and ensuring consistent product quality. Diversifying the supplier base and product portfolio could mitigate risks associated with over-reliance on a limited number of suppliers and products, enhancing Alloga UK Ltd's supply chain resilience and competitive position in the UK market.

2Requirements & Qualifications

Indian exporters seeking to supply Alloga UK Ltd and the United Kingdom market must obtain a Wholesale Distribution Authorisation (WDA(H)) from the MHRA and ensure that their manufacturing facilities hold a valid Good Manufacturing Practice (GMP) certificate recognized by the MHRA. Additionally, each medicinal product must have a valid Marketing Authorisation (MA) for sale in the UK. Compliance with these regulatory requirements is essential for entering the UK pharmaceutical market. (gov.uk)

3How to Approach

Frequently Asked Questions — Alloga UK Ltd

What products does Alloga UK Ltd import from India?

Alloga UK Ltd imports 6 pharmaceutical products across 4 categories. Top imports: Fexofenadine ($4.3M), Methotrexate ($2.8M), Salbutamol ($2.5M), Codeine ($1.2M), Fluticasone ($150.0K).

Who supplies pharmaceuticals to Alloga UK Ltd from India?

Alloga UK Ltd sources from 11 verified Indian suppliers. The primary supplier is Cipla Limited (84.1% of imports, $16.0M).

What is Alloga UK Ltd's total pharmaceutical import value?

Alloga UK Ltd's total pharmaceutical import value from India is $11.1M, based on 563 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Alloga UK Ltd focus on?

Alloga UK Ltd imports across 4 categories. The largest: Antihistamines & Allergy (38.7%), Immunosuppressants (25.3%), Respiratory (25.3%).

Get Full Alloga UK Ltd Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.